Navigation Links
Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation
Date:5/20/2011

FRAZER, Pa., May 20, 2011 /PRNewswire/ -- Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. (NASDAQ: CEPH), and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®.  The TRO remains in effect pending appeal.

"We are very pleased with the Court's decision to grant our request for a TRO," said Jerry Pappert, Executive Vice President and General Counsel for Cephalon.  "We remain confident in the strength of the patents protecting AMRIX®, and believe we have a strong case on appeal."

About Cephalon

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts:

Media:
Fritz Bittenbender
610-883-5855 (office)

610-457-7041 (cell)
fbittenb@cephalon.com

Natalie de Vane
610-727-6536 (office)
610-999-8756 (cell)
ndevane@cephalon.com

Investor Relations:
Chip Merritt
610-738-6376 (office)
cmerritt@cephalon.com

Joseph Marczely
610-883-5894 (office)
jmarczely@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
2. Cephalon Recommends Shareholders Reject Valeant Nominees
3. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
4. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
5. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
6. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
7. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
8. Cephalon Reports Record Earnings and Raises 2010 Guidance
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
11. Cephalon Completes Acquisition of Arana Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):